Do you want to read an article? Please log in or register.
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity
Leukemia
Related content
Leukemia
CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Am J Hematol.
Maffini E, Labopin M, Blaise D, Ciceri F, Gülbas Z, Deconinck E, Leblond V, Chevallier P, Sociè G, Araujo MC, Koc Y, Savani BN, Gorin NC, Lanza F, Nagler A, Mohty M
doi: 10.1002/ajh.25826.
Leukemia
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
J Clin Oncol.
Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, Ombrello A, Steinberg SM, Martin S, Delbrook C, Hoffman L, Little L, Ponduri A, Qin H, Qureshi H, Dulau-Florea A, Salem D, Wang HW, Yuan C, Stetler-Stevenson M, Panch S, Tran M, Mackall CL, Stroncek DF, Fry TJ
doi: 10.1200/JCO.19.03279.
RECOMMENDED
Leukemia
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
★ 1
Recommended by
Prof. Dr Christoph Renner, Faculty Member
doi: 10.3324/haematol.2019.243410.
Lymphoma
The CAR T Cell Story
healthbook TIMES Oncology Hematology
Russkamp N., Zenz T.
doi: 10.36000/hbT.OH.2019.01.001
RECOMMENDED
Leukemia
Toxicity and Response following CD19-specific CAR T cells in pediatric/young adult relapsed/refractory B-ALL
Blood.
Curran KJ, Margossian S, Kernan NA, Silverman LB, Williams DA, Shukla NN, Kobos R, Forlenza C, Steinherz P, Prockop S, Boulad F, Spitzer B, Cancio MI, Boelens JJ, Kung AL, Szenes VZ, Park J, Sauter CS, Heller G, Wang X, Senechal B, O'Reilly RJ, Riviere I, Sadelain M, Brentjens RJ
doi: 10.1182/blood.2019001641.
Leukemia
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS post-allogeneic transplant
Blood.
Lulla P, Naik S, Vasileiou S, Tzannou I, Watanabe A, Kuvalekar M, Lulla S, Carrum G, Ramos CA, Kamble R, Hill LC, Randhawa JK, Gottschalk S, Krance R, Tao W, Wu M, Robertson C, Gee AP, Chung BM, Grilley B, Brenner M, Heslop H, Vera JF, Leen AM
doi: 10.1182/blood.2020009471.
Central Nervous System Tumors
CD70, a novel target of CAR-T-cell therapy for gliomas
Neuro Oncol.
Jin L, Ge H, Long Y, Yang C, Chang YE, Mu L, Sayour EJ, De Leon G, Wang QJ, Yang JC, Kubilis PS, Bao H, Xia S, Lu D, Kong Y, Hu L, Shang Y, Jiang C, Nie J, Li S, Gu Y, Sun J, Mitchell DA, Lin Z, Huang J
doi: 10.1093/neuonc/nox116.
Leukemia
T-cell-depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT)
Cancer.
Sestili S, Labopin M, Ruggeri A, Velardi A, Ciceri F, Maertens J, Kanz L, Aversa F, Lewalle P, Bunjes D, Mohty M, Nagler A
doi: 10.1002/cncr.31310.
Leukemia
Dendritic cell vaccination as post-remission treatment to prevent or delay relapse in acute myeloid leukemia
Blood.
Anguille S, Van de Velde AL, Smits EL, Van Tendeloo VF, Juliusson G, Cools N, Nijs G, Stein B, Lion E, Van Driessche A, Vandenbosch I, Verlinden A, Gadisseur AP, Schroyens WA, Muylle L, Vermeulen K, Maes M, Deiteren K, Malfait R, Gostick E, Lammens M, Couttenye MM, Jorens P, Goossens H, Price DA, Ladell K, Oka Y, Fujiki F, Oji Y, Sugiyama H, Berneman ZN
doi: 10.1182/